Abstract |
We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30 mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score <or=7. At 12 weeks, response was achieved by 79.5% of the patients (n=35) and remission by 36.4% of patients (n=16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.
|
Authors | Francesco Gambi, Domenico De Berardis, Daniela Campanella, Alessandro Carano, Gianna Sepede, Gabriele Salini, Daniela Mezzano, Alessandra Cicconetti, Laura Penna, Rosa Maria Salerno, Filippo Maria Ferro |
Journal | Journal of psychopharmacology (Oxford, England)
(J Psychopharmacol)
Vol. 19
Issue 5
Pg. 483-7
(Sep 2005)
ISSN: 0269-8811 [Print] United States |
PMID | 16166185
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents, Tricyclic
- Mianserin
- Mirtazapine
|
Topics |
- Adult
- Antidepressive Agents, Tricyclic
(adverse effects, therapeutic use)
- Anxiety Disorders
(drug therapy, psychology)
- Appetite
(drug effects)
- Constipation
(chemically induced)
- Female
- Humans
- Male
- Mianserin
(adverse effects, analogs & derivatives, therapeutic use)
- Mirtazapine
- Outpatients
- Psychiatric Status Rating Scales
- Sleep Stages
(drug effects)
- Treatment Outcome
- Weight Gain
(drug effects)
- Xerostomia
(chemically induced)
|